A detailed history of Parallel Advisors, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 10,195 shares of EXEL stock, worth $339,391. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,195
Previous 5,675 79.65%
Holding current value
$339,391
Previous $127,000 107.87%
% of portfolio
0.01%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$21.96 - $27.6 $99,259 - $124,752
4,520 Added 79.65%
10,195 $264,000
Q2 2024

Aug 08, 2024

BUY
$20.34 - $23.73 $59,758 - $69,718
2,938 Added 107.34%
5,675 $127,000
Q1 2024

May 06, 2024

BUY
$20.17 - $23.93 $20,048 - $23,786
994 Added 57.03%
2,737 $64,000
Q4 2023

Feb 09, 2024

SELL
$19.25 - $24.13 $29,702 - $37,232
-1,543 Reduced 46.96%
1,743 $41,000
Q3 2023

May 20, 2024

BUY
$19.04 - $22.74 $28,122 - $33,586
1,477 Added 81.65%
3,286 $71,000
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $28,122 - $33,586
1,477 Added 81.65%
3,286 $71,000
Q2 2023

May 20, 2024

BUY
$18.17 - $20.48 $11,356 - $12,800
625 Added 52.79%
1,809 $34,000
Q2 2023

Aug 04, 2023

BUY
$18.17 - $20.48 $11,356 - $12,800
625 Added 52.79%
1,809 $34,000
Q1 2023

May 20, 2024

SELL
$16.3 - $19.41 $25,313 - $30,143
-1,553 Reduced 56.74%
1,184 $22,000
Q1 2023

Apr 25, 2023

SELL
$16.3 - $19.41 $33,480 - $39,868
-2,054 Reduced 63.43%
1,184 $22,000
Q4 2022

Feb 03, 2023

BUY
$14.96 - $17.39 $7,943 - $9,234
531 Added 19.62%
3,238 $51,000
Q3 2022

Nov 10, 2022

BUY
$15.68 - $22.27 $7,024 - $9,976
448 Added 19.83%
2,707 $42,000
Q2 2022

Aug 01, 2022

SELL
$17.44 - $23.16 $11,545 - $15,331
-662 Reduced 22.66%
2,259 $47,000
Q1 2022

Apr 28, 2022

BUY
$17.03 - $22.67 $2,707 - $3,604
159 Added 5.76%
2,921 $66,000
Q4 2021

Jan 20, 2022

BUY
$15.84 - $21.88 $36,178 - $49,973
2,284 Added 477.82%
2,762 $50,000
Q3 2021

Nov 02, 2021

SELL
$16.3 - $21.14 $652 - $845
-40 Reduced 7.72%
478 $10,000
Q2 2021

Aug 06, 2021

SELL
$17.95 - $25.56 $753 - $1,073
-42 Reduced 7.5%
518 $9,000
Q1 2021

Apr 23, 2021

BUY
$20.53 - $25.22 $3,161 - $3,883
154 Added 37.93%
560 $13,000
Q4 2020

Feb 02, 2021

BUY
$18.39 - $24.8 $882 - $1,190
48 Added 13.41%
406 $8,000
Q3 2020

Oct 27, 2020

SELL
$20.67 - $26.94 $1,777 - $2,316
-86 Reduced 19.37%
358 $9,000
Q2 2020

Jul 16, 2020

BUY
$16.46 - $27.42 $1,744 - $2,906
106 Added 31.36%
444 $10,000
Q1 2020

Apr 27, 2020

BUY
$14.46 - $21.8 $4,121 - $6,213
285 Added 537.74%
338 $5,000
Q4 2019

Jan 30, 2020

SELL
$15.15 - $18.89 $2,075 - $2,587
-137 Reduced 72.11%
53 $1,000
Q3 2019

Nov 01, 2019

BUY
$17.68 - $22.65 $265 - $339
15 Added 8.57%
190 $3,000
Q4 2018

Feb 05, 2019

BUY
$13.65 - $21.8 $696 - $1,111
51 Added 41.13%
175 $3,000
Q2 2018

Jul 30, 2018

BUY
$18.56 - $22.45 $1,392 - $1,683
75 Added 153.06%
124 $2,000
Q1 2018

May 08, 2018

SELL
$22.15 - $31.89 $1,993 - $2,870
-90 Reduced 64.75%
49 $1,000
Q3 2017

Nov 15, 2017

BUY
$23.35 - $29.24 $3,245 - $4,064
139 New
139 $4,000
Q3 2017

Nov 14, 2017

SELL
$23.35 - $29.24 $1,144 - $1,432
-49 Closed
0 $0
Q2 2017

Aug 07, 2017

BUY
N/A
49
49 $1,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.